|
Originally published In Press as doi:10.1074/jbc.M106609200 on November 1, 2001
J. Biol. Chem., Vol. 277, Issue 2, 1340-1348, January 11, 2002
Phosphorylation of Inositol 1,4,5-Trisphosphate Receptors in
Parotid Acinar Cells
A MECHANISM FOR THE SYNERGISTIC EFFECTS OF cAMP ON
Ca2+ SIGNALING*
Jason I. E.
Bruce ,
Trevor J.
Shuttleworth,
David
R.
Giovannucci, and
David I.
Yule
From the Department of Pharmacology & Physiology, School of
Medicine and Dentistry, University of Rochester Medical Center,
Rochester, New York 14642
Received for publication, July 13, 2001, and in revised form, October 29, 2001
 |
ABSTRACT |
Acetylcholine-evoked secretion from the parotid
gland is substantially potentiated by cAMP-raising agonists. A
potential locus for the action of cAMP is the intracellular signaling
pathway resulting in elevated cytosolic calcium levels
([Ca2+]i). This hypothesis
was tested in mouse parotid acinar cells. Forskolin dramatically
potentiated the carbachol-evoked increase in
[Ca2+]i, converted oscillatory
[Ca2+]i changes into a sustained
[Ca2+]i increase, and caused
subthreshold concentrations of carbachol to increase
[Ca2+]i measurably. This
potentiation was found to be independent of Ca2+ entry and
inositol 1,4,5-trisphosphate (InsP3) production, suggesting that cAMP-mediated effects on Ca2+ release was the major
underlying mechanism. Consistent with this hypothesis, dibutyryl cAMP
dramatically potentiated InsP3-evoked Ca2+
release from streptolysin-O-permeabilized cells. Furthermore, type II
InsP3 receptors (InsP3R) were shown to be
directly phosphorylated by a protein kinase A (PKA)-mediated mechanism
after treatment with forskolin. In contrast, no evidence was obtained
to support direct PKA-mediated activation of ryanodine receptors
(RyRs). However, inhibition of RyRs in intact cells, demonstrated a
role for RyRs in propagating Ca2+ oscillations and
amplifying potentiated Ca2+ release from
InsP3Rs. These data indicate that potentiation of Ca2+ release is primarily the result of PKA-mediated
phosphorylation of InsP3Rs, and may largely explain the
synergistic relationship between cAMP-raising agonists and
acetylcholine-evoked secretion in the parotid. In addition, this report
supports the emerging consensus that phosphorylation at the
level of the Ca2+ release machinery is a broadly important
mechanism by which cells can regulate Ca2+-mediated processes.
 |
INTRODUCTION |
Calcium is a ubiquitous second messenger that is critically
important in the regulation of a variety of cellular functions (1-3).
The spatio-temporal "shaping" of Ca2+ signals is
thought to play an important role in defining the specificity of
stimulus-response coupling both between cell types and within the same
cell (4, 5). However, despite intensive investigation, the molecular
mechanisms that control frequency- and/or amplitude-encoded
Ca2+ oscillations, Ca2+ wave propagation, or
localized Ca2+ release events remain poorly understood. An
emerging body of evidence indicates that, in various systems, specific
control over Ca2+ signals may be achieved by cross-talk
between second messenger systems that raise
[Ca2+]i 1
interacting with those that elevate cAMP. Such cross-talk may alter the
sensitivity of a variety of Ca2+ transport processes (6,
7).
An example of this cross-talk occurs in the salivary gland, where both
fluid and exocytotic secretion are controlled by separate neuronal
and/or humoral inputs (6, 8). Specifically, neuronally released
acetylcholine (ACh) activates acinar cell muscarinic receptors, leading
to increased [Ca2+]i via the
phosphoinositide pathway. Elevations in
[Ca2+]i activate ion channels
essential for unidirectional fluid secretion (9), and, in addition,
exert regulatory control over the exocytotic machinery required for
protein secretion (6). Muscarinic activation of both fluid secretion,
and to a lesser extent exocytosis, has been shown to be dramatically
potentiated by the concomitant activation of cAMP-raising pathways,
such as by co-released vasoactive intestinal peptide, or by sympathetic stimulation of -adrenoreceptors (10-13). Although cAMP could have direct effects on ion channels (14) and/or exocytotic proteins (15), an
alternative hypothesis is that cAMP interacts directly with the
Ca2+ signaling machinery to account for the synergistic
effects (6, 13, 16). Because parotid acinar cells have been used
extensively to study Ca2+ signaling, this model system is
ideally suited to investigate cross-talk between cAMP and
Ca2+ signaling.
InsP3 production, Ca2+ influx, and
Ca2+ release from either InsP3Rs or RyRs, are
all potential targets for cAMP in modulating Ca2+signaling,
however, the literature is equivocal as to the site of any interaction
(16-23). No single study has been successful in unambiguously
identifying a specific molecular target that accounts for the
synergistic relationship between cAMP and Ca2+ signaling in
parotid acinar cells. Therefore, the aim of the present study was to
investigate the molecular target(s) for the interaction between cAMP
and Ca2+ signaling in mouse parotid acinar cells. This was
achieved using a combination of imaging (intact and SL-O-permeabilized
cells), inositol phosphate assays and in situ
phosphorylation experiments. These experimental paradigms revealed that
cAMP dramatically potentiated Ca2+ release through
PKA-mediated phosphorylation of InsP3 receptors, likely the
type II isoform. This regulatory control likely underlies the
synergistic relationship between ACh and cAMP-elevating agonists in
parotid acinar cells. These findings have broad implications and may
represent a general feature for the regulation of Ca2+
release events that are linked to a vast array of specific functions in
all cell types.
 |
EXPERIMENTAL PROCEDURES |
Isolation of Single Parotid Acinar Cells--
Single and small
groups of parotid acinar cells were isolated by collagenase digestion
of freshly dissected parotid glands from wild type Swiss Black mice
using a technique similar to that described previously for rat parotid
(24). Briefly, 25-g mice were killed by cardiac puncture immediately
following CO2 gas asphyxiation. Parotid glands were
dissected, minced, and incubated for 60 min at 37 °C in Earle's
minimum essential medium (Biofluids, Inc., Rockville, MD) containing 2 mM glutamine, 1% bovine serum albumin, and 0.04 mg/ml
collagenase P (Roche Molecular Biochemicals, Mannheim, Germany). Minced
tissue was dispersed by multiple trituration every 20 min. Cells were
resuspended in bovine serum albumin-free Eagle's basal medium
(Invitrogen) supplemented with 2 mM glutamine and
penicillin/streptomycin and left on ice until ready for use.
Digital Imaging of
[Ca2+]i--
Isolated parotid acinar cells
were resuspended in a HEPES-buffered physiological saline solution
(HEPES-PSS) containing (in mM) 5.5 glucose, 137 NaCl, 0.56 MgCl2, 4.7 KCl, 1 Na2HPO4, 10 HEPES
(pH 7.4), 1.2 CaCl2. The cells were then incubated in the above HEPES-PSS containing 2 µM fura-2/AM for 30 min at
room temperature, after which they were washed once and resuspended in
the above HEPES-PSS and kept on ice. Cells were allowed to adhere to a
glass coverslip that formed the base of a gravity-fed perfusion chamber and continually perfused with HEPES-PSS. [Ca2+] imaging
was performed using an inverted epifluorescence Nikon microscope with a
40× oil immersion objective lens (numerical aperture, 1.3). A field of
3-15 fura-2-loaded cells was excited alternately with light at 340 and
380 nm (± 10 nm bandpass filters, Chroma) using an illumination system
(Sutter, DG-4). Fluorescence images (500 ± 45 nm) were captured
and digitized at 12-bit resolution using an interline progressive scan
CCD camera (Sensicam). Axon Imaging Workbench was used to drive the
DG-4 and image acquisition by the camera. Images were acquired every
second with an exposure of 200 ms. Background-subtracted and 340/380
ratio images were calculated on-line and stored immediately to hard
disk. Images (480 × 640 pixels) were collected with no binning,
thereby giving a spatial resolution of 0.225 µm/pixel. All
experiments were performed at room temperature.
Measurement of Intra-ER Ca2+([Ca2+]ER)--
Isolated parotid
acinar cells were incubated in the above attachment media containing 10 µM fura-2FF/AM (KD for
Ca2+ ~13 µM; see Ref. 25) for 60 min at
37 °C. Permeabilization and subsequent Ca2+ uptake and
Ca2+ release experiments were similar to those reported in
pancreatic acinar cells (26, 27). Briefly, cells were constantly
perfused with a Chelex-100 "scrubbed" cytosol-like medium
containing (in mM) 135 KCl, 1.2 KH2PO4, 0.5 EGTA, 0.5 HEDTA, 0.5 nitriloacetic acid, and 20 HEPES/KOH (pH 7.1). MgCl2, CaCl2,
and MgATP were added accordingly to give a constant free
Mg2+, Ca2+, and ATP concentration of 0.9 mM, 200 nM, and 1 mM, respectively (as calculated by WEBMAXC version 2.1). Permeabilization was achieved by perfusion with an ATP-containing (but Ca2+-free)
cytosol-like medium containing 0.4 IU of streptolysin-O (SL-O).
Permeabilization was monitored and verified using the imaging system by
exciting loaded cells with light at 360 nm, which is the isosbestic
point for fura-2FF (360 ± 25 nm bandpass filter, Chroma). Images were
acquired every 10 s (100-ms exposure) and the fluorescence in each
cell monitored over time. The emitted fluorescence declined rapidly
within 10 min as the plasma membrane permeabilized and all the
cytosolic dye leaked out of the cell. The resultant fluorescence
(<20% of pre-permeabilized cells) was caused by dye trapped in
intracellular organelles. The cells were subsequently perfused with the
cytosol-like medium devoid of SL-O, Ca2+, or ATP for 10 min. Measurement of [Ca2+]ER was achieved by
exciting permeabilized cells with light at 340 and 380 nm as with
fura-2, except images were acquired every 10 s with an exposure of
300 ms. This was done to prevent photobleaching of the dye because
emitted fluorescence was significantly lower than when the dye was
trapped in the cytosol. Rapid Ca2+ uptake was achieved upon
addition of 1 mM Mg-ATP and 0.2 µM
Ca2+, reaching a steady state within 3 min. Upon loading
the stores with Ca2+, permeabilized cells were stimulated
with various concentrations of InsP3 in the absence or
presence of 100 µM dibutyryl cyclic AMP
(Bt2cAMP), 10 µM Rp-cAMPS, and/or 500 µM ryanodine. Ca2+ release was measured as a
decrease in the fura-2FF 340/380 ratio.
Measurement of Inositol Phosphate Production--
Total inositol
phosphate production in response to forskolin and/or carbachol (CCh)
was determined by a similar method to that described previously (28).
Briefly, isolated parotid acinar cells were incubated with 5 µCi/ml
myo-[3H]inositol for 2 h, followed by
three washes in HEPES-PSS. Cells were then incubated with 1 µM CCh and/or 10 µM forskolin for 5 min in
the presence of 10 mM lithium. Total
myo-[3H]inositol phosphates from each sample
were extracted by solubilization with 0.5 M trichloroacetic
acid, eluted on Dowex columns and detected by liquid scintillation.
Total inositol phosphate generation was expressed as a percentage of
total phosphoinositides, determined by counting the trichloroacetic
acid-insoluble fraction by liquid scintillation.
Phosphorylation of Ca2+ Release
Channels--
Parotid acinar cells were isolated from 4 mice as
described above and metabolically labeled by incubating for 2 h
with 14 µCi/ml 32PO (PerkinElmer Life
Sciences) in a phosphate-free saline solution containing (in
mM) 109.7 NaCl, 4.5 KCl, 1.2 MgCl2, 5.95 HEPES
(free acid), 7.05 NaHEPES (pH 7.4) 1.13 CaCl2 and 6 glucose. Following incubation, cells were washed three times in the
above 32PO -free media and aliquots
treated with or without 10 µM forskolin for 10 min at
37 °C. Cells were then rapidly pelleted by centrifugation and
resuspended in ice-cold lysis buffer containing (in mM) 50 Tris-HCl (pH 7.4), 250 NaCl, 5 EDTA, 100 NaF, 1 benzamidine, 1 dithiothreitol, 1% CHAPS, 10 µg/ml phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 0.7 µg/ml pepstatin A, 1 µg/ml aprotinin, 1 µg/ml antipain. Cell lysates were then sonicated, left on ice for 30 min, and vortexed every 5 min. InsP3R or RyR protein was
immunoprecipitated from the samples by incubating lysates with a
mixture of antibodies (~1 µg of antibody/mg of protein) raised
against all three InsP3R types or all three RyR types for
1 h at 4 °C, followed by incubation with 80 µl of protein
A-agarose beads (Pierce) for an additional 1 h at 4 °C. Antibodies directed against InsP3R were CT1 and
CT2 (kind gifts from Richard Wojcikiewicz, State University
of New York, Syracuse, NY) and type III antibody (Transduction
Laboratories). Antibodies directed against RyR were 34C directed
against RyR1 (Developmental Studies Hybridoma Bank, Iowa
City, IA), C3-33 directed against RyR2 (Affinity
Bioreagents, Inc.), and anti-rabbit skeletal muscle RyR antibody
directed against RyR3 (Upstate Biotechnology, Lake Placid,
NY). As a secondary control, aliquots of cell lysate from cells treated
with forskolin were incubated with beads without any antibodies.
Following incubation, the beads-protein complexes were washed five
times in lysis buffer by repeated centrifugation and resuspension and
then boiled in SDS-sample buffer (Laemmli). Immunoprecipitated proteins
were separated by SDS-polyacrylamide gel (5%) electrophoresis
(SDS-PAGE), after which the gels were vacuum-dried (Bio-Rad) and
exposed to a PhosphorImager intensifier screen. Bands of the
appropriate molecular weight, which corresponded to phosphorylated
proteins that had incorporated 32PO ,
were detected using a Molecular Dynamics PhosphorImager.
To determine whether phosphorylation of InsP3Rs was
mediated by PKA, H-89 and Rp-cAMPS were used to inhibit PKA in
combination with an additional and complimentary approach using a
phospho-PKA substrate antibody (Cell Signaling Technology). This
antibody specifically recognizes proteins containing phosphorylated
serine or threonine, with an arginine residue at position 3, but not the corresponding nonphosphorylated motif (29, 30). Although this
antibody would not discriminate between substrates of PKA, protein
kinase C, or cyclic GMP-dependent protein kinase, the combined use of forskolin and appropriate PKA inhibitors was used to
implicate a specific role of PKA. Aliquots of isolated parotid acinar
cells were treated with or without 10 µM forskolin, 50 nM okadaic acid, and/or the PKA inhibitors, H-89 (2 µM) and Rp-cAMPS (30 µM) for 10 min at
37 °C. Cells were then solubilized in lysis buffer similar to the
method above. Lysates were then incubated with phospho-PKA substrate
antibody (1:100 dilution) to immunoprecipitate phosphorylated proteins.
Specific detection of phosphorylated type II InsP3Rs was
achieved by Western blotting with the CT2 antibody. Whole
cell lysates or immunoprecipitated proteins were denatured in
SDS-sample buffer, separated by SDS-PAGE, and transferred to
nitrocellulose (Schleicher & Schuell) prior to immunoblotting with the
CT2 antibody. Immunoreactivity was visualized using
peroxidase-conjugated secondary antibodies (Bio-Rad), followed by
detection by Super Signal detection system (Pierce) exposed on XAR film
(Eastman Kodak Co.).
Data Analysis and Experimental Design--
In all experiments
(unless otherwise stated in the text), a paired experimental design was
applied, whereby a particular experimental paradigm was repeated in the
absence or presence of a test reagent(s) on the same cell. Therefore,
statistical significance was determined, where appropriate, using a
paired t test, Wilcoxon test for pairs, or one sample
t test. Occasionally, statistical significance was determined between groups of experiments where an unpaired t
test or Mann-Whitney test was used. For any parameter analyzed from several cells in a particular experiment, an average value was determined. These values were in turn averaged to give the values expressed in the text as means ± S.E.
 |
RESULTS |
Carbachol-evoked [Ca2+]i Changes--
To
investigate the effects of elevated cAMP levels on
[Ca2+]i signaling in parotid
acinar cells, we first characterized the types of
[Ca2+]i responses evoked by the
muscarinic receptor agonist, CCh. Low concentrations of CCh (10-300
nM) caused an oscillatory increase in
[Ca2+]i in 86% of cells tested,
which was characterized by a large initial spike followed by rapid
sinusoidal oscillations superimposed over an elevated base line. These
oscillations were complex in nature, and their frequency and amplitude
varied markedly between cells. Higher concentrations of CCh (300 nM to 10 µM) induced a biphasic increase in
[Ca2+]i, which was characterized
by a large initial spike followed by a sustained elevation. These
patterns of [Ca2+]i changes are
typical of a variety of exocrine cells; however, the oscillation
frequency was significantly higher than reported in pancreatic acinar
cells (7-11/min in parotid compared with 4-6/min; see Ref. 31).
Despite the complex nature of these CCh-evoked
[Ca2+]i changes, there was a
consistent concentration-dependent increase in the
magnitude of the initial spike-like increase in [Ca2+]i. This initial
[Ca2+]i spike was interpreted to
reflect Ca2+ release from intracellular stores and was
quantitatively compared in the absence and presence of 10 µM forskolin using a paired experimental design.
Forskolin Potentiates Carbachol-evoked
[Ca2+]i Changes--
Using the adenylate
cyclase activator forskolin, we investigated the effects of elevating
intracellular cAMP levels on CCh-evoked [Ca2+]i signaling (33). Repeated
stimulations with CCh evoked [Ca2+]i changes of equal magnitude
(Fig. 1). Forskolin (10 µM)
induced a dramatic and time-dependent potentiation of this CCh-evoked initial increase in
[Ca2+]i. Upon removal of
forskolin, there was an equivalent time-dependent recovery
(Fig. 1). On average, forskolin increased the CCh-evoked
[Ca2+]i response by 148.9 ± 8.5% after 3-5 min, which increased further to 177.1 ± 17.4%
after 8-10 min of incubation with forskolin (see Fig. 1). To test
whether the potentiation was the result of specific activation of PKA,
cells were also pretreated with 2 µM H-89, an inhibitor
of serine/threonine kinases such as PKA (34) prior to specific
activation of PKA by treatment with forskolin. This completely
prevented the potentiation of the CCh-evoked initial increase in
[Ca2+]i (Fig.
2), suggesting that the potentiation was
caused by activation of PKA.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
Forskolin causes potentiation of CCh-evoked
[Ca2+]i changes in mouse
parotid acinar cells. A, stimulation of cells with a
low (0.3 µM) and higher (1 µM)
concentration of CCh demonstrated a steep concentration-response effect
of CCh on [Ca2+]i. Repeated
stimulations with CCh in the absence (CCh-1 and CCh-2 in B)
and presence of 10 µM forskolin (forsk-1 and forsk-2 in
B) illustrate the dramatic potentiation of the initial peak
CCh evoked [Ca2+]i response and
subsequent recovery (wash-1 and wash-2 in B) after removal
of forskolin. B, quantification of mean data (13 experiments, 87 cells) was achieved by expressing each CCh-evoked
initial [Ca2+]i increase as a % of the first control CCh (CCh-1) response in the same cell. Statistical
significance was determined using a paired one sample t test
(*p < 0.05).
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 2.
A PKA inhibitor prevents the
potentiation of the CCh-evoked
[Ca2+]i response by
forskolin. Using a similar experimental paradigm as Fig. 1, cells
were pretreated with 2 µM H-89 for 5 min prior to
treatment with 10 µM forskolin in combination with 2 µM H-89 for at least 5 min. A, representative
trace from 6 separate experiments (24 cells). B,
quantification of mean data revealed that the PKA inhibitor, H-89
completely prevented the potentiation by forskolin. Statistical
significance was determined using a paired one sample t test
(*p < 0.05).
|
|
In addition to the potentiation of the CCh-evoked initial increase in
[Ca2+]i, forskolin also converted
oscillatory [Ca2+]i changes into a
sustained increase, suggesting a leftward shift in the CCh
concentration-response curve compared with control cells (Fig.
3A). Consistent with this
hypothesis, forskolin treatment enabled normally subthreshold
concentrations of CCh (3-30 nM) to evoke oscillatory
[Ca2+]i responses (49 of 75 cells). Interestingly, in six of these cells,
[Ca2+]i oscillations were confined
to the apical region of the cells (Fig. 3B), revealing
conversion of a subthreshold response into a measurable threshold
response. To identify the molecular site at which this potentiation was
manifested, we systematically investigated the effects of forskolin on
Ca2+ entry, InsP3 production, and
Ca2+ release channels in parotid acinar cells using a
variety of biochemical and functional assays.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
Forskolin sensitizes the CCh-evoked
[Ca2+]i response.
A, forskolin converted an oscillatory
[Ca2+]i response into a sustained
[Ca2+]i response in all cells
tested (7 experiments, 58 cells). The dotted line represents
a gap of 7 to 9 min during which no images were acquired. B,
treatment with forskolin also resulted in a response to sub-threshold
concentrations of CCh (10-30 µM) being converted from
nonresponding to an oscillatory
[Ca2+]i response (49 of 75 cells,
11 experiments). The trace is representative of 6 of these cells (2 experiments) where the oscillations were confined to the apical region
of the cell. The red and blue trace represent the
changes in [Ca2+]i defined by the
corresponding red and blue boxes in the above
brightfield image. The red and blue boxes
represent the apical and basal region respectively of a single
cell that is part of a small clump or acini. The above pseudo-color
enhanced fluorescence ratio images were the corresponding images at
a, b and c on the trace.
|
|
Effects of Forskolin on Ca2+ Entry--
A potential
locus for the effects of cAMP on Ca2+ signals is the
Ca2+ entry pathways. Stimulation of parotid acinar cells
with low concentrations of CCh (100 nM) in
Ca2+-free solution (nominal Ca2+) evoked
[Ca2+]i oscillations. These
oscillations progressively decreased in amplitude (Fig.
4A), presumably in response to
depletion of intracellular stores. Re-introduction of external
Ca2+ in the continued presence of CCh produced a large
increase in base-line [Ca2+]i with
oscillations of increasing amplitude superimposed (Fig. 4A).
The elevated base-line [Ca2+]i was
interpreted to reflect capacitative Ca2+ entry. Repeating
this paradigm in the presence of 10 µM forskolin caused a
169.3 ± 6.5% potentiation of the initial CCh-evoked
[Ca2+]i increase, which was not
significantly different from that observed in the presence of external
Ca2+ (177.1 ± 17.4%; Fig. 4B) This
suggests that enhanced Ca2+ release, rather than
Ca2+ entry, was responsible for potentiation of the initial
CCh-evoked [Ca2+]i increase.
Re-introduction of external Ca2+ in the presence of
forskolin produced a potentiation of the elevated base-line
[Ca2+]i (Fig. 4, A and
B; 122.1 ± 11.3% higher than control), suggesting an
effect on capacitative Ca2+ entry. This most likely
reflected an indirect effect, resulting from the enhanced
Ca2+ release and store depletion, on Ca2+
entry. However, additional direct effects of cAMP on Ca2+
entry cannot be completely excluded.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Ca2+ entry is not directly
affected by forskolin treatment. A, representative
experiment showing the effect of removal and subsequent re-introduction
of external [Ca2+] on the CCh-evoked
[Ca2+]i response in the absence
and presence of forskolin. The dotted line represents a gap of 7 to 9 min during which no images were acquired. B, quantification
of mean data revealed that the initial CCh-evoked
[Ca2+]i increase was dramatically
potentiated by forskolin even in the absence of external
[Ca2+] (171 ± 13% increase, 4 experiments, 14 cells; * p < 0.05 determined by paired one sample
t test). However this was not significantly different from
the potentiation of the initial CCh-evoked
[Ca2+]i increase by forskolin in
the presence of external [Ca2+] (177 ± 17%
increase from Fig. 1, statistical significance determined by unpaired
Mann Whitney test).
|
|
Effects of Forskolin on InsP3
Production--
Activation of muscarinic receptors leads to the
generation of InsP3 through G-protein-coupled activation of
phospholipase C (PLC). Thus, the effects of forskolin could conceivably
be caused by an interaction of cAMP with this receptor-signaling
complex leading to an enhancement of InsP3 generation. To
test this idea we examined the effects of forskolin on inositol
phosphate production by measuring [3H]inositol
incorporation to assess PLC activity and thus InsP3 production. CCh (1 µM) significantly increased inositol
phosphates from 5.9 ± 0.2 to 9.8 ± 0.1% of total
phosphoinositides (Fig. 5). In contrast,
forskolin (10 µM) had no effect on either basal (6.1 ± 0.1%) or CCh-evoked (8.9 ± 0.3%) inositol phosphate turnover (Fig. 5). This indicated that increased cAMP does not directly stimulate the production of inositol phosphates and suggests a likely
site of action is the Ca2+ release process itself.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
InsP3 generation is not directly
affected by forskolin treatment. [3H]Inositol
phosphate production, measured by incorporation of
[3H]inositol into phospholipid, was assessed as an
indirect measure of InsP3 generation. Inositol phosphate
production was expressed as % of total phosphoinositides. 1 µM CCh significantly increased inositol phosphates from
5.9 ± 0.2% to 9.8 ± 0.1% of total phosphoinositides.
Forskolin alone (6.1 ± 0.1%) or in combination with 1 µM CCh (8.9 ± 0.3%) did not significantly affect
inositol phosphate production. Statistical significance was determined
by unpaired students t test (* p < 0.05, n = 3).
|
|
Effects of Ryanodine on Carbachol-evoked
[Ca2+]i Changes--
In nonexcitable cells,
InsP3Rs are generally thought to be the trigger for
Ca2+ release, whereas RyRs may have a role in propagating
further release by Ca2+-induced Ca2+ release
(CICR) (35). We pharmacologically separated these two Ca2+
release pathways by inhibiting RyRs with 500 µM ryanodine
(36). Ryanodine alone failed to significantly affect the initial
increase in [Ca2+]i evoked by CCh
(101.5 ± 7.3%; Fig. 6,
A and C), suggesting that this event does not
involve RyRs. However, when applied during a train of Ca2+
oscillations, ryanodine dramatically dampened the oscillatory [Ca2+]i response (Fig. 6,
A and B). These data therefore imply that RyRs
may be important for propagating and maintaining Ca2+
oscillations in parotid acinar cells as is the case in pancreatic acinar cells (32).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of inhibition of RyRs on CCh-evoked
[Ca2+]i responses and the
potentiation by forskolin. A, 500 µM ryanodine
dampened the oscillatory [Ca2+]i
response but failed to significantly affect the initial CCh-evoked
[Ca2+]i increase. B,
using a similar experimental paradigm and in combination with 10 µM forskolin, ryanodine reduced the potentiation of the
initial CCh-evoked [Ca2+]i
increase by forskolin. The dotted line represents a gap of 7 to 9 min during which no images were acquired. C,
quantification of mean data confirmed that ryanodine failed to
significantly affect the initial CCh-evoked
[Ca2+]i increase (101.5 ± 7.3% increase), but significantly reduced the potentiation by
forskolin (125.2 ± 2.8% increase compared with 177.1 ± 17.4% in the absence of ryanodine; p < 0.05 as
determined by Mann Whitney test). However the residual potentiation in
the presence of both ryanodine and forskolin remained significant
(*p < 0.05 as determined by one sampled t
test).
|
|
When applied in combination with 10 µM forskolin,
ryanodine significantly reduced the potentiation of the CCh-evoked
[Ca2+]i response from 177.1 ± 17.4% to 125.2 ± 2.8% of that observed in the absence of
forskolin and ryanodine (Fig. 6, B and C).
Nevertheless, the residual potentiation (125.2 ± 2.8%) remained
significantly different from control. One possible interpretation of
these data is that the potentiation of Ca2+ release by
forskolin is caused by a direct effect of PKA on both RyRs and
InsP3Rs.
Direct Activation of RyR--
To address whether the potentiation
by forskolin was caused by a direct effect of PKA on RyRs, we attempted
to selectively activate RyRs. Caffeine (20 mM,
n = 5 experiments, 22 cells) or low concentrations of
ryanodine (0.01-10 µM, n = 8 experiments, 49 cells) consistently failed to affect resting
[Ca2+]i either in the absence or
presence of forskolin (Fig. 7,
A and B). In addition, 10 µM
forskolin failed to affect resting [Ca2+]i in any cell tested either
in the presence or absence of ryanodine (data not shown). Because the
effects of ryanodine are use-dependent (see Ref. 36, and
references therein), two separate approaches were utilized to
facilitate activation of RyRs. First, 10 µM ryanodine was
added during a train of CCh-evoked [Ca2+]i oscillations (see Fig.
7C) and continually applied after CCh was removed (similarly
to Ref. 37). The second approach was to increase external
[Ca2+] to 10 mM in an attempt to
progressively elevate resting
[Ca2+]i, thereby increasing the
sensitivity of RyRs to ryanodine (see Fig. 7D). However,
ryanodine, either alone or in combination with forskolin, failed to
affect resting [Ca2+]i in any cell
tested (see Fig. 7, C (three separate experiments, 15 cells)
and D (four separate experiments, 29 cells). In contrast to
conventional activators, such as caffeine or ryanodine, 4-chloro-m-cresol (CmC), a compound well documented to
specifically activate RyRs (38-41), caused slow,
concentration-dependent and readily reversible increases in
resting [Ca2+]i (Fig.
7E, three experiments, 14 cells). However, in contrast to
CCh-evoked [Ca2+]i increases, 10 µM forskolin failed to significantly affect the
CmC-evoked [Ca2+]i increases (Fig.
7F, five experiments, 33 cells). This indicates that
RyR-mediated Ca2+ release in mouse parotid acinar cells is
not directly affected by raising cAMP with forskolin, and suggests that
PKA has a direct effect on InsP3Rs. The role of RyRs may
simply be to amplify the enhanced Ca2+ release from
InsP3Rs by CICR.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
Attempts to directly activate RyRs fail to
show any potentiation by forskolin. Representative experiments
using several different paradigms to directly activate RyRs in the
absence of InsP3R activation failed to evoke any change in
[Ca2+]i either in the absence or
presence of 10 µM forskolin; using A, 20 mM caffeine (5 experiments, 22 cells), B, low
concentrations of ryanodine (0.01-10 µM; 8 experiments,
49 cells), C, application of ryanodine during a train of
CCh-evoked [Ca2+]i oscillations (3 experiments, 15 cells), D, application of ryanodine when
external [Ca2+] was elevated to 10 mM (4 experiments, 29 cells). E,
concentration-dependent increase in resting
[Ca2+]i evoked by CmC; (three
experiments, 14 cells). F, 10 µM forskolin
failed to affect 300 µM CmC-evoked increase in resting
[Ca2+]i (5 experiments, 33 cells).
|
|
InsP3-evoked Ca2+ Release from
SL-O-permeabilized Cells--
To directly assess the effects of cAMP
on InsP3-evoked Ca2+ release,
SL-O-permeabilized cells were used. Despite permeabilization, cells
retained their polarity as indicated by apically located secretory
granules. Following permeabilization, fluorescence became both
dramatically reduced (<20%) and highly punctate, indicative of dye
trapped within organelles (26, 42). Perfusion of permeabilized cells
with a "cytosolic-like" medium devoid of Ca2+ and ATP
caused a slow decline in the fura-2FF-340/380 ratio, which stabilized
in 5-10 min, indicating Ca2+ store depletion. The
subsequent addition of 0.2 µM Ca2+ and 1 mM Mg-ATP evoked a rapid increase in fura-2FF-340/380 ratio that reached a steady state within 3 min (Fig.
8, A-E), reflecting rapid
uptake of Ca2+ into the ER. The observed rate was
significantly faster than that reported in pancreatic acinar cells
(~10 min to reach steady state; see Refs. 26 and 27).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 8.
InsP3-evoked Ca2+
release from SL-O-permeabilized cells is dramatically potentiated by
Bt2cAMP, but unaffected by ryanodine. Perfusion of
SL-O-permeabilized parotid acinar cells with 0.2 µM
Ca2+ and 1 mM MgATP evoked rapid uptake of
Ca2+ (indicated by arrow, A-E). Subsequent
application of InsP3 evoked a rapid decrease in fura-2FF
340/380 ratio, indicative of Ca2+ release. A paired
experimental design was utilized whereby a low concentration (0.3 µM), followed by a high concentration (3 µM) of InsP3 was applied first in the absence
and then in the presence of treatment on the same cell. A to
E are representative experiments showing time-matched
controls (A, 4 experiments, 21 cells), effects of 100 µM Bt2cAMP (B, 5 experiments, 5 cells), the combined effect of Bt2cAMP and Rp-cAMPS
(C, 4 experiments, 17 cells), 500 µM ryanodine
(D, 4 experiments, 20 cells) and the combined effect of
Bt2cAMP and ryanodine (E, 4 experiments, 17 cells) on InsP3-evoked Ca2+ release.
F, quantification of mean data was achieved by expressing
InsP3-evoked Ca2+ release in the presence of
treatment (or 2nd control) relative to that in the absence of treatment
(or 1st control) in the same cell. Statistical significance was
determined using a paired one sample t test
(*p < 0.05). This revealed that Ca2+
release was unaltered by repeated stimulation with InsP3
either over time (0.3 µM, 0.94 ± 0.06-fold change;
3.0 µM, 0.96 ± 0.03-fold change), or following
treatment with 500 µM ryanodine (0.3 µM,
1.02 ± 0.05-fold change; 3.0 µM, 0.93 ± 0.05-fold change). However, 100 µM Bt2cAMP
dramatically potentiated Ca2+ release evoked by 0.3 µM InsP3 (3.0 ± 0.5-fold change) but
not by 3 µM InsP3 (0.95 ± 0.06-fold
change). The potentiation by Bt2cAMP (3.0 ± 0.5-fold
change) was prevented by Rp-cAMPS (1.1 ± 0.2-fold change) but not
affected by co-treatment with ryanodine (2.37 ± 0.16-fold change)
as compared using an unpaired Mann Whitney test. Inset shows
mean InsP3 concentration-response curve, where
Ca2+ release was expressed as % of the maximum evoked by
10 µM InsP3, which gave an EC50
of 0.64 ± 0.11 µM InsP3.
|
|
Following Ca2+ uptake, InsP3 (0.1-10
µM) evoked a concentration-dependent stepwise
decrease in [Ca2+]ER. For each experiment,
mean data were fit to a sigmoidal dose-response curve from which a mean
half-maximum concentration (EC50) was determined (Fig.
8F, inset; five separate experiments, 41 cells). This revealed a very steep InsP3 concentration-response
relationship for Ca2+ release with an EC50 of
0.64 ± 0.11 µM and maximal release at 10 µM InsP3, similar to previous reports (22,
43, 44). InsP3-evoked Ca2+ release was also
readily reversible, because removal of InsP3 in the
continued presence of Ca2+ and ATP caused a rapid return of
[Ca2+]ER to near pre-stimulatory levels,
suggesting Ca2+ was rapidly taken back up into the ER (Fig.
8, A-F). This allowed the application of a general
experimental paradigm consisting of stimulating with a low dose of
InsP3 (0.3 µM), which evoked 24.2 ± 0.1% maximal release, followed by a high dose (3 µM),
which evoked nearly maximal release (93.1 ± 0.2%; Fig.
8F, inset). This paradigm was then repeated in
the presence of 100 µM Bt2cAMP (Fig. 8B) with or without 10 µM Rp-cAMPS or 500 µM ryanodine (Fig. 8, C-E). Time-matched
controls were performed to account for loss of dye, photobleaching, or
possible desensitization (Fig. 8A). Fig. 8F shows
the mean data expressed as -fold increase in Ca2+ released
by 0.3 and 3.0 µM InsP3. Time-matched
controls revealed that repeated stimulations with InsP3
were not significantly different (Fig. 8, A and
F). In contrast 100 µM Bt2cAMP
dramatically potentiated Ca2+ release evoked by 0.3 µM InsP3 (3.0 ± 0.5-fold increase; Fig. 8, B and F) but did not significantly effect
Ca2+ release evoked by 3 µM InsP3
(0.95 ± 0.06-fold; Fig. 8F). This suggested that cAMP
increased the sensitivity of InsP3-evoked Ca2+
release without affecting the capacity of the stores to release Ca2+. Consistent with the effects of forskolin in intact
cells, Bt2cAMP failed to evoke Ca2+ release
when applied in the absence of InsP3 (Fig. 8B).
In addition, 10 µM Rp-cAMPS, an inhibitor of PKA that
competes for the cAMP-binding site (45), completely prevented the
potentiation of InsP3-evoked Ca2+ release by
Bt2cAMP (Fig. 8, C and F). This is
further supportive of data from intact cells suggesting that the
potentiation is PKA-mediated.
Similar to the effects of ryanodine on CCh-evoked Ca2+
release in intact cells, ryanodine also failed to significantly affect Ca2+ release from permeabilized cells evoked by either 0.3 µM (1.02 ± 0.05-fold change) or 3 µM
InsP3 (0.93 ± 0.05-fold change; Fig. 8, D
and F (four separate experiments, 20 cells)). However, in contrast to intact cells, ryanodine failed to affect the potentiation of InsP3-evoked Ca2+ release by
Bt2cAMP; release stimulated by 0.3 µM
InsP3 increased 2.37 ± 0.16-fold, whereas release
stimulated by 3 µM InsP3 was unaffected
(1.04 ± 0.01-fold; Fig. 8, E and F (four
separate experiments, 17 cells). Therefore, the lack of effect of
ryanodine in SL-O-permeabilized cells suggests that, under these
conditions, RyRs are functionally uncoupled from InsP3Rs.
Collectively, these data add credence to the notion that
InsP3Rs, and not RyRs, are directly modulated by PKA.
In Situ Phosphorylation of InsP3R and RyRs--
To
examine whether the potentiation of Ca2+ release correlated
with PKA-mediated phosphorylation of InsP3Rs and/or RyRs,
two complimentary approaches were adopted using receptor specific antibodies to immunoprecipitate potentially phosphorylated protein. First, cells were metabolically labeled with
32PO and protein that had incorporated 32PO upon phosphorylation was detected by autoradiography. Following treatment with forskolin and subsequent immunoprecipitation with InsP3R-specific antibodies, there
was enhanced labeling of bands at the expected molecular weight for InsP3Rs compared with control (Fig.
9A). This demonstrates that InsP3Rs are directly phosphorylated, presumably by a
PKA-mediated process. In contrast, under similar conditions using
RyR-specific antibodies, no detectable signal was observed at the
appropriate molecular weight for RyRs. Immunoprecipitation of RyR
protein from skeletal muscle, cardiac muscle, and brain tissue lysates confirmed the avidity of RyR-specific antibody (data not shown).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 9.
PKA-mediated phosphorylation of
InsP3Rs by treatment with forskolin. A, parotid
acini, metabolically labeled with 32PO ,
were incubated with (+) or without ( ) 10 µM forskolin
for 10 min and samples were prepared as detailed under "Experimental
Procedures." Treatment with forskolin dramatically increased the
intensity of a band representative of a ~250 kDa protein, indicative
of phosphorylated InsP3Rs. B, verification of
Phospho-PKA substrate antibody in detecting phosphorylated proteins
upon treatment of cells with (+) or without ( ) 10 µM
forskolin, 2 µM H-89, 30 µM Rp-cAMPS and/or
50 nM okadaic acid. Cell lysates were prepared as detailed
under "Experimental Procedures," and protein samples run on a 7.5%
SDS-polyacrylamide gel. Phosphorylated proteins were detected by
Western blotting with the Phospho-PKA substrate antibody. C,
detection of phosphorylated type II InsP3Rs upon treatment
of cells with (+) or without ( ) 10 µM forskolin, 2 µM H-89 or 30 µM Rp-cAMPS. Phosphorylated
proteins were immunoprecipitated with the Phospho-PKA substrate
antibody, run on a 5% SDS-polyacrylamide gel and phosphorylated type
II InsP3Rs were detected by Western blotting with the
CT2 antibody. * in A and C represent
a secondary control whereby samples were treated identically but
immunoprecipitating antibodies were omitted and represent nonspecific
binding to protein-A beads.
|
|
Second, an alternative and complimentary approach used the phospho-PKA
substrate antibody to immunoprecipitate phosphorylated protein,
followed by specific detection of phosphorylated type II
InsP3R by immunoblot with the CT2 antibody. The
specificity of the phospho-PKA substrate antibody for phosphorylated
protein was verified in Fig. 9B. A variety of proteins of
different molecular weight were detected upon treatment with forskolin
compared with untreated cells even though equal amounts of total
protein were added into each lane (Fig. 9B, lane
3 versus lane 1). The phospho-PKA substrate antibody
does not distinguish between substrates of PKA, protein kinase C, and
cyclic GMP-dependent protein kinase (29, 30). To
distinguish between activation of these kinases, cells were treated
with the PKA inhibitors H-89 (2 µM) and Rp-cAMPS (30 µM) prior to and in the continued presence of forskolin
to specifically activate PKA. This completely prevented the detection of visible bands (Fig. 9B, lane 4), which
strongly suggests that forskolin evokes PKA-mediated phosphorylation of
proteins. Furthermore, treatment of cells with the protein phosphatase
inhibitor okadaic acid (50 nM) did not dramatically
increase protein phosphorylation, suggesting that basal protein
phosphatase activity was low and not affected by cell lysis (Fig.
9B, lanes 5 and 6). Finally, immunoprecipitation with the phospho-PKA substrate antibody and subsequent immunoblot with CT2 antibody showed that
forskolin dramatically increased the detection of phosphorylated type
II InsP3R (Fig. 9C, lanes 4 and
5), which was prevented by pretreatment with H-89 and
Rp-cAMPS (Fig. 9C, lanes 6 and 7).
Taken together, these data provide convincing evidence that forskolin
causes PKA-mediated phosphorylation of type II InsP3R.
 |
DISCUSSION |
The present study provides functional and molecular evidence
defining a specific site at which cAMP-raising agonists exert synergistic regulatory control over fluid secretion and exocytosis in
mouse parotid acinar cells stimulated by muscarinic activation of
[Ca2+]i signaling (10-13, 16).
The signal transduction pathway following muscarinic receptor
stimulation and leading to an increase in intracellular
Ca2+ is a rich source of sites for possible PKA regulation,
which could account for the dramatic PKA-mediated potentiation of the CCh-evoked initial [Ca2+]i
increase. The effects of raising cAMP on various aspects of this
signaling pathway were therefore systematically investigated. Specifically, Ca2+ entry has been suggested to be important
not only in replenishing the stores with Ca2+ but also in
maintaining agonist-evoked sustained
[Ca2+]i signals (4, 46), and in
modulating the frequency of
[Ca2+]i oscillations by
sensitizing Ca2+ release (47). In addition, in hepatocytes
(48) and submandibular acinar cells (49), cAMP has been shown to
potentiate InsP3 production. However, in the present study,
forskolin treatment was shown to have no appreciable effect on
Ca2+ entry or CCh-evoked PLC activity and InsP3
production. These data led us to conclude that the primary site of
action of PKA is on the Ca2+ release process itself.
InsP3-evoked Ca2+ release from
InsP3Rs underlies agonist-induced increases in
[Ca2+]i in a variety of
nonexcitable cells including secretory epithelia (4, 32). We observed
in a proportion of cells that forskolin altered the sensitivity of
CCh-evoked [Ca2+]i signals in such
a way that apically confined
[Ca2+]i signals were initiated
from subthreshold CCh concentrations. In a variety of exocrine cells,
the apical region is regarded as the "trigger zone" from which
Ca2+ waves are initiated (32, 50, 51). Conceptually, such a region could be established by the relative abundance of
Ca2+ release channels and/or expression of the most
sensitive channels. Both of these criteria are satisfied in rat parotid
acinar cells; immunocytochemical studies have reported that the extreme
apical region is highly enriched in all InsP3R types (18,
19). Furthermore, of the three InsP3Rs expressed, the type
II InsP3R, which has been reported to be the most sensitive
to InsP3 (52, 53), is the most abundant InsP3R
type in parotid acinar cells (18). Collectively, this supports the idea
that cAMP potentiates Ca2+ release from the most sensitive
InsP3Rs located in the apical region of the cell.
Ca2+-induced Ca2+ release is important for the
generation of both localized "spikes" and global increases in
[Ca2+]i (4, 32), and it is
conceivable that modulation of CICR could contribute to the observed
cAMP-mediated potentiation. Although InsP3Rs themselves
possess all the properties to support CICR (54), there is an emerging
body of evidence that RyRs are important for CICR in nonexcitable cells
(5, 35, 55). Both InsP3Rs and RyRs have been shown to
contain putative consensus sequences for phosphorylation by PKA (56,
57) and in some cases phosphorylation results in enhanced release
(58-60). However, in mouse parotid acinar cells, we found that
inhibition of RyRs with high concentrations of ryanodine failed to
significantly affect the CCh-evoked initial increase in
[Ca2+]i, consistent with the
notion that the mechanism underlying this release primarily involves
InsP3Rs. When applied during a train of Ca2+
oscillations, however, ryanodine dramatically inhibited oscillations, similarly to previous studies (35, 61). Of particular interest, ryanodine significantly reduced the potentiation of the CCh-evoked [Ca2+]i response by forskolin
(Fig. 6). An obvious explanation for this result is the
direct phosphorylation of RyRs by PKA. However, we were unable to
obtain any functional or biochemical evidence for this phosphorylation
in parotid acinar cells. For example, various maneuvers designed to
isolate Ca2+ release through RyR were not augmented by
raising cAMP levels, and attempts to demonstrate direct phosphorylation
of RyRs were unsuccessful. How can the effects of ryanodine on the
initial PKA-potentiated release be reconciled with these data? One
possibility is that the apparent contribution of RyRs after PKA
treatment is simply the result of the enhanced release of
Ca2+ by InsP3Rs, resulting in an increased
[Ca2+] in the vicinity of RyR, thereby increasing the
possibility of CICR. This implies that RyRs in parotid acinar cells act
to amplify Ca2+ signals that originate from the primary
trigger source, which is InsP3Rs, but only do so when a
threshold [Ca2+]i (or microdomain
of Ca2+) is established. This is consistent with studies
showing that RyR3 is the predominant RyR type expressed in
mouse parotid acinar cells, albeit in relatively low abundance compared
with skeletal muscle (62). Single-channel data indicate that
RyR3 exhibit very low activity at [Ca2+]
lower than 1 µM, but are dramatically activated by
[Ca2+] above 1 µM (63). As such, RyRs would
be functionally uncoupled at rest and only become activated by
microdomains of Ca2+ created by Ca2+ released
from neighboring InsP3Rs.
Activation of PKA with Bt2cAMP failed to evoke
Ca2+ release from SL-O-permeabilized cells (Fig.
8B), a result consistent with the lack of effect of
forskolin in intact cells and in agreement with similar studies using
imaging of calcium green C18-labeled permeabilized parotid acinar cells
(20). In contrast, cAMP has been demonstrated to evoke Ca2+
release from static suspensions of permeabilized cells and microsomal vesicles of rat parotid acinar cells (18, 21-23), a result that was
attributed to activation of RyRs. Of interest in these studies is the
fact that cAMP elevation evoked a relatively small Ca2+
release (~35 nM) compared with InsP3 (~150
nM) (18, 21) and that this release occurred under
conditions where basal [Ca2+] was estimated to be as high
as 431 nM (22). At these [Ca2+], any RyRs
would be expected to be in a sensitized state. The discrepancy between
the present study and the aforementioned report underscores the
difficulty in extrapolating averaged Ca2+ release from
permeabilized cell suspensions to Ca2+ release in intact
cells where resting [Ca2+]i is
likely to be closer to ~100 nM. Alternatively, the
presence of such a ryanodine-sensitive cAMP-dependent
Ca2+ release pathway, not observed in this study, may
simply be the result of species differences. As stated previously,
mouse parotid acinar cells express predominantly RyR3 (62),
whereas rat parotid acinar cells (revealed by reverse
transcription-PCR) express predominantly RyR1 (21). Because
RyR1 exhibit a lower threshold for activation by
Ca2+ (63), any potentiation of Ca2+ release by
cAMP would be amplified under conditions of elevated resting
[Ca2+]i (18, 21, 22). Such species
differences could also explain the lack of effect of caffeine in mouse
acinar cells, as RyR3 are thought to be
caffeine-insensitive (64, 65).
The lack of effect of ryanodine on InsP3-evoked
Ca2+ release in SL-O-permeabilized parotid acinar cells
suggests that InsP3Rs and RyRs are functionally uncoupled
under these conditions, presumably as a result of high perfusion rates
resulting in an effective infinite volume mimicking the cytoplasm. As
such, microdomains of Ca2+ will likely fail to establish at
sufficiently high levels to evoke CICR. In addition, many cytosolic
components such as mobile buffers, which may be important for CICR,
will be lost in permeabilized cells. Thus, this system allowed us to
study the functioning of InsP3Rs in isolation. The data
obtained indicate that the potentiation of CCh-evoked
[Ca2+]i signals is mediated
through InsP3Rs, because activation of PKA still revealed
potentiation under conditions where RyRs were functionally uncoupled.
In support of this, treatment with forskolin caused phosphorylation of
type II InsP3Rs; the weight of evidence presented suggests
a PKA-mediated mechanism. There is an emerging consensus
that PKA may regulate Ca2+ release events directly at the
level of the Ca2+ release channel. Previous studies have
shown that InsP3Rs contain several consensus sequences for
PKA-mediated phosphorylation (56) and can be phosphorylated both
in vitro (66, 67) and in vivo (68, 69). However,
there exists no clear consensus as to the physiological consequence of
InsP3R-type-specific phosphorylation in terms of
Ca2+ release. For example, phosphorylation of type I
InsP3R from cerebellum caused a decrease in
Ca2+ release (66, 70), whereas others have shown an
increase in Ca2+release (71). In addition, phosphorylation
of type III InsP3R in pancreatic acinar cells results in
reduced Ca2+ release at low doses of InsP3
(72), whereas phosphorylation of type II InsP3R in liver
enhances Ca2+ release (58, 60). This latter observation is
of particular interest to the present study, as the type II
InsP3Rs are the dominant form expressed in parotid acinar
cells (18). Despite that in vitro phosphorylation studies
revealed that type II InsP3Rs were relatively poor
substrates for PKA phosphorylation (69), the present study convincingly
demonstrated that forskolin treatment causes PKA-mediated
phosphorylation of type II InsP3Rs in mouse parotid acinar cells.
In summary, PKA-mediated phosphorylation of type II InsP3Rs
is a predominant mechanism for the potentiation of Ca2+
signaling in mouse parotid acinar cells. This largely explains the
synergistic relationship between cAMP-raising agonists and ACh-evoked
secretion in the parotid. These findings support the emerging consensus
that phosphoregulation of InsP3Rs is an important mechanism
underlying the "shaping" of Ca2+ signals, and thus have
broad implications for the fidelity of Ca2+-mediated processes.
 |
ACKNOWLEDGEMENTS |
The RyR antibody (clone 34C), developed by J. Airey and J. Sutko, was obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the NICHD, National
Institutes of Health (Bethesda, MD) and maintained by the Department of
Biological Sciences, University of Iowa (Iowa City, IA). We thank Dr.
R. J. H. Wojcikiewicz for providing InsP3R
antibodies (CT1 and CT2), Jodi Pilato for
preparation of single parotid acinar cells, Jill Thompson for help with
inositol phosphate and in situ phosphorylation experiments,
Pauline Leakey and Sarah Wolbert for excellent technical assistance,
and Dr. Patricia Hinkle and Steve Straub for helpful comments on the manuscript.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants DEO 13539 (to T. J. S. and D. I. Y.), GM
40457 (to T. J. S.), and DK54568 (to D. I. Y.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pharmacology
& Physiology, School of Medicine and Dentistry, University of Rochester
Medical Center, 601 Elmwood Ave., Rochester, NY 14642. Tel.:
716-275-6128; Fax: 716-273-2652; E-mail:
jason_bruce@urmc.rochester.edu.
Published, JBC Papers in Press, November 1, 2001, DOI 10.1074/jbc.M106609200
 |
ABBREVIATIONS |
The abbreviations used are:
[Ca2+]i, intracellular calcium
concentration;
InsP3, inositol 1,4,5-trisphosphate;
InsP3R, inositol 1,4,5-trisphosphate receptor;
ACh, acetylcholine;
CCh, carbamylcholine (carbachol);
PKA, protein kinase A;
RyR, ryanodine receptor;
Bt2cAMP, dibutyryl cAMP;
SL-O, streptolysin-O, CICR, calcium-induced calcium release;
PLC, phospholipase C;
CmC, 4-choro-m-cresol;
ER, endoplasmic
reticulum;
PSS, physiological saline solution;
HEDTA, N-(2-hydroxyethyl)ethylenediaminetriacetic acid;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
Rp-cAMPS, Rp-adenosine-3:5'-cylic
monophosphorothioate.
 |
REFERENCES |
| 1.
|
Clapham, D. E.
(1995)
Cell
80,
259-268
|
| 2.
|
Penner, R.,
and Neher, E.
(1988)
J. Exp. Biol.
139,
329-345
|
| 3.
|
Hardingham, G. E.,
Chawla, S.,
Johnson, C. M.,
and Bading, H.
(1997)
Nature
385,
260-265
|
| 4.
|
Putney, J. W. J.
(1998)
Science
279,
191-192
|
| 5.
|
Berridge, M. J.
(1997)
Nature
386,
759-760
|
| 6.
|
Putney, J. W. J.
(1986)
Annu. Rev. Physiol.
48,
75-88
|
| 7.
|
Bugrim, A. E.
(1999)
Cell Calcium
25,
219-226
|
| 8.
|
Baum, B. J.
(1987)
in
The Salivary System
(Sreenby, L. M., ed)
, pp. 123-134, CRC Press, Inc., Boca Raton, FL
|
| 9.
|
Petersen, O. H.,
and Gallacher, D. V.
(1988)
Annu. Rev. Physiol.
50,
65-80
|
| 10.
|
Larsson, O.,
and Olgart, L.
(1989)
Acta Physiol. Scand.
137,
231-236
|
| 11.
|
Bobyock, E.,
and Chernick, W. S.
(1989)
J. Dent. Res.
68,
1489-1494
|
| 12.
|
Baldys-Waligorska, A.,
Pour, A.,
Moriarty, C. M.,
and Dowd, F.
(1987)
Biochim. Biophys. Acta
929,
190-196
|
| 13.
|
Yoshimura, K.,
Hiramatsu, Y.,
and Murakami, M.
(1998)
Biochim. Biophys. Acta
1402,
171-187
|
| 14.
|
Kraus-Friedmann, N.
(2000)
Cell Calcium
27,
127-138
|
| 15.
|
Fujita-Yoshigaki, J.
(1998)
Cell Signal.
10,
371-375
|
| 16.
|
McKinney, J. S.,
Desole, M. S.,
and Rubin, R. P.
(1989)
Am. J. Physiol.
257,
C651-C657
|
| 17.
|
Tanimura, A.,
Nezu, A.,
Tojyo, Y.,
and Matsumoto, Y.
(1999)
Am. J. Physiol.
276,
C1282-C1287
|
| 18.
|
Zhang, X.,
Wen, J.,
Bidasee, K. R.,
Besch, H. R., Jr.,
Wojcikiewicz, R. J. H.,
Lee, B.,
and Rubin, R. P.
(1999)
Biochem. J.
340,
519-527
|
| 19.
|
Takemura, H.,
Yamashina, S.,
and Segawa, A.
(1999)
Biochem. Biophys. Res. Commun.
259,
656-660
|
| 20.
|
Tojyo, Y.,
Tanimura, A.,
Nezu, A.,
and Matsumoto, Y.
(1998)
Eur. J. Pharmacol.
360,
73-79
|
| 21.
|
Zhang, X.,
Wen, J.,
Bidasee, K. R.,
Besch, H. R. J.,
and Rubin, R. P.
(1997)
Am. J. Physiol.
273,
C1306-C1314
|
| 22.
|
Rubin, R. P.,
and Adolf, M. A.
(1994)
J. Pharmacol. Exp. Ther.
268,
600-606
|
| 23.
|
Ozawa, T.
(1998)
Biochem. Biophys. Res. Commun.
246,
422-425
|
| 24.
|
Evans, R. L.,
Bell, S. M.,
Schultheis, P. J.,
Shull, G. E.,
and Melvin, J. E.
(1999)
J. Biol. Chem.
274,
29025-29030
|
| 25.
|
Hyrc, K. L.,
Bownik, J. M.,
and Goldberg, M. P.
(2000)
Cell Calcium
27,
75-86
|
| 26.
|
van de Put, F. H.,
and Elliott, A. C.
(1996)
J. Biol. Chem.
271,
4999-5006
|
| 27.
|
van de Put, F. H.,
and Elliott, A. C.
(1997)
J. Biol. Chem.
272,
27764-27770
|
| 28.
|
Shuttleworth, T. J.,
and Thompson, J. L.
(1998)
J. Biol. Chem.
273,
32636-32643
|
| 29.
|
Montminy, M.
(1997)
Annu. Rev. Biochem.
66,
807-822
|
| 30.
|
Pearson, R. B.,
and Kemp, B. E.
(1991)
Methods Enzymol.
200,
62-81
|
| 31.
|
Yule, D. I.,
Lawrie, A. M.,
and Gallacher, D. V.
(1991)
Cell Calcium
12,
145-151
|
| 32.
|
Lee, M.-G., Xu, X.,
Zeng, W.,
Diaz, J.,
Wojcikiewicz, R. J. H.,
Kuo, T. H.,
Wuytack, R.,
Racymaekers, L.,
and Muallem, M.
(1997)
J. Biol. Chem.
272,
15765-15770
|
| 33.
|
Seamon, K. B.,
Padgett, W.,
and Daly, J. W.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
3363-3367
|
| 34.
|
Davies, S. P.,
Reddy, H.,
Caivano, M.,
and Cohen, P.
(2000)
Biochem. J.
351,
95-105
|
| 35.
|
Straub, S. V.,
Giovannucci, D. R.,
and Yule, D. I.
(2000)
J. Gen. Physiol.
116,
547-560
|
| 36.
|
Zucchi, R.,
and Ronca-Testoni, S.
(1997)
Pharmacol. Rev.
49,
1-51
|
| 37.
|
Verma, V.,
Carter, C.,
Keable, S.,
Bennett, D.,
and Thorn, P.
(1996)
Biochem. J.
319,
449-454
|
| 38.
|
Zorzato, F.,
Scutari, E.,
Tegazzin, V.,
Clementi, E.,
and Treves, S.
(1993)
Mol. Pharmacol.
44,
1192-1201
|
| 39.
|
Westerblad, H.,
Andrade, F. H.,
and Islam, M. S.
(1998)
Cell Calcium
24,
105-115
|
| 40.
|
Li, G.,
Wollheim, C. B.,
and Pralong, W. F.
(1996)
Cell Calcium
19,
535-546
|
| 41.
|
Sei, Y.,
Gallagher, K. L.,
and Basile, A. S.
(1999)
J. Biol. Chem.
274,
5995-6002
|
| 42.
|
Tojyo, Y.,
Tanimura, A.,
and Matsumoto, Y.
(1997)
Biochem. Biophys. Res. Commun.
240,
189-195
|
| 43.
|
Hofer, A. M.,
and Machen, T. E.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
2598-2602
|
| 44.
|
Menniti, F. S.,
Bird, G. S.,
Takemura, H.,
Thastrup, O.,
Potter, B. V.,
and Putney, J. W. J.
(1991)
J. Biol. Chem.
266,
13646-13653
|
| 45.
|
Botelho, L. H.,
Rothermel, J. D.,
Coombs, R. V.,
and Jastorff, B.
(1988)
Methods Enzymol.
159,
159-172
|
| 46.
|
Berridge, M. J.
(1995)
Biochem. J.
312,
1-11
|
| 47.
|
Shuttleworth, T. J.
(1999)
Cell Calcium
25,
237-246
|
| 48.
|
Pittner, R. A.,
and Fain, J. N.
(1989)
Biochem. J.
257,
455-460
|
| 49.
|
Martinez, RJ.,
and Zhang, G. H.
(1998)
Eur. J. Morphol.
36,
190-193
|
| 50.
|
Kasai, H., Li, Y. X.,
and Miyashita, Y.
(1993)
Cell
74,
669-677
|
| 51.
|
Tojyo, Y.,
Tanimura, A.,
and Matsumoto, Y.
(1997)
Cell Calcium
22,
455-462
|
| 52.
|
Sudhof, T. C.,
Newton, C. L.,
Archer, B. T.,
Ushkaryov, Y. A.,
and Mignery, G. A.
(1991)
EMBO J.
10,
3199-3206
|
| 53.
|
Newton, C. L.,
Mignery, G. A.,
and Sudhof, T. C.
(1994)
J. Biol. Chem.
269,
28613-28619
|
| 54.
|
Bezprozvanny, I.,
Watras, J.,
and Ehrlich, B. E.
(1991)
Nature
351,
751-754
|
| 55.
|
Nathanson, M. H.,
Padfield, P. J.,
O'Sullivan, A. J.,
Burgstahler, A. D.,
and Jamieson, J. D.
(1992)
J. Biol. Chem.
267,
18118-18121
|
| 56.
|
Furuichi, T.,
Yoshikawa, S.,
Miyawaki, A.,
Wada, K.,
Maeda,
and Mikoshiba, K.
(1989)
Nature
342,
32-38
|
| 57.
|
Suko, J.,
Maurer-Fogy, I.,
Plank, B.,
Bertel, O.,
Wyskovsky, W.,
Hohenegger, M.,
and Hellmann, G.
(1993)
Biochim. Biophys. Acta
1175,
193-206
|
| 58.
|
Hajnoczky, G.,
Gao, E.,
Nomura, T.,
Hoek, J. B.,
and Thomas, A. P.
(1993)
Biochem. J.
293,
413-422
|
| 59.
|
Marx, S. O.,
Reiken, S.,
Hisamatsu, Y.,
Jayaraman, T.,
Burkhoff, D.,
Rosemblit, N.,
and Marks, A. R.
(2000)
Cell
101,
365-376
|
| 60.
|
Burgess, G. M.,
Bird, G. S.,
Obie, J. F.,
and Putney, J. W. J.
(1991)
J. Biol. Chem.
266,
4772-4781
|
| 61.
|
Thorn, P.,
Gerasimenko, O.,
and Petersen, O. H.
(1994)
EMBO J.
13,
2038-2043
|
| 62.
|
DiJulio, D. H.,
Watson, E. L.,
Pessah, I. N.,
Jacobson, K. L.,
Ott, S. M.,
Buck, E. D.,
and Singh, J. C.
(1997)
J. Biol. Chem.
272,
15687-15696
|
| 63.
|
Sonnleitner, A.,
Conti, A.,
Bertocchini, F.,
Schindler, H.,
and Sorrentino, V.
(1998)
EMBO J.
17,
2790-2798
|
| 64.
|
Giannini, G.,
Clementi, E.,
Ceci, R.,
Marziali, G.,
and Sorrentino, V.
(1992)
Science
257,
91-94
|
| 65.
|
Hakamata, Y.,
Nishimura, S.,
Nakai, J.,
Nakashima, Y.,
Kita, T.,
and Imoto, K.
(1994)
FEBS Lett.
352,
206-210
|
| 66.
|
Suppattapone, S.,
Danoff, S. K.,
Theibert, A.,
Joseph, S. K.,
Steiner, J.,
and Snyder, S. H.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
8747-8750
|
| 67.
|
Ferris, C. D.,
Huganir, R. L.,
Bredt, D. S.,
Cameron, A. M.,
and Snyder, S. H.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
2232-2235
|
| 68.
|
Joseph, S. K.,
and Ryan, SV.
(1993)
J. Biol. Chem.
268,
23059-23065
|
| 69.
|
Wojcikiewicz, R. J. H.,
and Luo, S. G.
(1998)
J. Biol. Chem.
273,
5670-5677
|
| 70.
|
Volpe, P.,
and Anderson-Lange.
(1990)
Am. J. Physiol.
258,
C1086-C1091
|
| 71.
|
Nakade, S.,
Rhee, S. K.,
Hamanaka, H.,
and Mikoshiba, K.
(1994)
J. Biol. Chem.
269,
6735-6742
|
| 72.
|
Giovannucci, D. R.,
Groblewski, G. E.,
Sneyd, J.,
and Yule, D. I.
(2000)
J. Biol. Chem.
275,
33704-33711
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Saino and E. L. Watson
Inhibition of serine/threonine phosphatase enhances arachidonic acid-induced [Ca2+]i via protein kinase A
Am J Physiol Cell Physiol,
January 1, 2009;
296(1):
C88 - C96.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Farquhar, H. J. Harris, M. Diskar, S. Jones, C. J. Mee, S. U. Nielsen, C. L. Brimacombe, S. Molina, G. L. Toms, P. Maurel, et al.
Protein Kinase A-Dependent Step(s) in Hepatitis C Virus Entry and Infectivity
J. Virol.,
September 1, 2008;
82(17):
8797 - 8811.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Warner, C. G. Peters, R. Saunders, J. H. Won, M. J. Betzenhauser, W. T. Gunning III, D. I. Yule, and D. R. Giovannucci
Visualizing form and function in organotypic slices of the adult mouse parotid gland
Am J Physiol Gastrointest Liver Physiol,
September 1, 2008;
295(3):
G629 - G640.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. Wagner II, S. K. Joseph, and D. I. Yule
Regulation of single inositol 1,4,5-trisphosphate receptor channel activity by protein kinase A phosphorylation
J. Physiol.,
August 1, 2008;
586(15):
3577 - 3596.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. U. Shah, W. M. Grant, S. U. Latif, Z. M. Mannan, A. J. Park, and S. Z. Husain
Cyclic AMP accelerates calcium waves in pancreatic acinar cells
Am J Physiol Gastrointest Liver Physiol,
June 1, 2008;
294(6):
G1328 - G1334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ishibashi, K. Okamura, and J. Yamazaki
Involvement of apical P2Y2 receptor-regulated CFTR activity in muscarinic stimulation of Cl- reabsorption in rat submandibular gland
Am J Physiol Regulatory Integrative Comp Physiol,
May 1, 2008;
294(5):
R1729 - R1736.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Shintani, C. Hirono, M. Sugita, Y. Iwasa, and Y. Shiba
Suppression of carbachol-induced oscillatory Cl- secretion by forskolin in rat parotid and submandibular acinar cells
Am J Physiol Gastrointest Liver Physiol,
March 1, 2008;
294(3):
G738 - G747.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Baggaley, S. McLarnon, I. Demeter, G. Varga, and J. I. E. Bruce
Differential Regulation of the Apical Plasma Membrane Ca2+-ATPase by Protein Kinase A in Parotid Acinar Cells
J. Biol. Chem.,
December 28, 2007;
282(52):
37678 - 37693.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. G. Romanenko, T. Nakamoto, A. Srivastava, T. Begenisich, and J. E. Melvin
Regulation of membrane potential and fluid secretion by Ca2+-activated K+ channels in mouse submandibular glands
J. Physiol.,
June 1, 2007;
581(2):
801 - 817.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-S. Chun, J. K. Akunda, and R. Langenbach
Cyclooxygenase-2 Inhibits UVB-Induced Apoptosis in Mouse Skin by Activating the Prostaglandin E2 Receptors, EP2 and EP4
Cancer Res.,
March 1, 2007;
67(5):
2015 - 2021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Fiser, J. Masin, M. Basler, J. Krusek, V. Spulakova, I. Konopasek, and P. Sebo
Third Activity of Bordetella Adenylate Cyclase (AC) Toxin-Hemolysin: MEMBRANE TRANSLOCATION OF AC DOMAIN POLYPEPTIDE PROMOTES CALCIUM INFLUX INTO CD11b+ MONOCYTES INDEPENDENTLY OF THE CATALYTIC AND HEMOLYTIC ACTIVITIES
J. Biol. Chem.,
February 2, 2007;
282(5):
2808 - 2820.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ishibashi, J. Yamazaki, K. Okamura, Y. Teng, K. Kitamura, and K. Abe
Roles of CLCA and CFTR in Electrolyte Re-absorption from Rat Saliva
Journal of Dental Research,
December 1, 2006;
85(12):
1101 - 1105.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Romanenko, T. Nakamoto, A. Srivastava, J. E. Melvin, and T. Begenisich
Molecular Identification and Physiological Roles of Parotid Acinar Cell Maxi-K Channels
J. Biol. Chem.,
September 22, 2006;
281(38):
27964 - 27972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Gonzalez-Iglesias, Y. Jiang, M. Tomic, K. Kretschmannova, S. A. Andric, H. Zemkova, and S. S. Stojilkovic
Dependence of Electrical Activity and Calcium Influx-Controlled Prolactin Release on Adenylyl Cyclase Signaling Pathway in Pituitary Lactotrophs
Mol. Endocrinol.,
September 1, 2006;
20(9):
2231 - 2246.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Won and D. I. Yule
Measurement of Ca2+ signaling dynamics in exocrine cells with total internal reflection microscopy
Am J Physiol Gastrointest Liver Physiol,
July 1, 2006;
291(1):
G146 - G155.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Thompson and T. Begenisich
Membrane-delimited Inhibition of Maxi-K Channel Activity by the Intermediate Conductance Ca2+-activated K Channel
J. Gen. Physiol.,
January 30, 2006;
127(2):
159 - 169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gerbino, W. C. Ruder, S. Curci, T. Pozzan, M. Zaccolo, and A. M. Hofer
Termination of cAMP signals by Ca2+ and G{alpha}i via extracellular Ca2+ sensors: a link to intracellular Ca2+ oscillations
J. Cell Biol.,
October 24, 2005;
171(2):
303 - 312.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F.L.C. Moseley, K.N. Jha, L. Bjorndahl, I.A. Brewis, S.J. Publicover, C.L.R. Barratt, and L. Lefievre
Protein tyrosine phosphorylation, hyperactivation and progesterone-induced acrosome reaction are enhanced in IVF media: an effect that is not associated with an increase in protein kinase A activation
Mol. Hum. Reprod.,
July 1, 2005;
11(7):
523 - 529.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Monteiro, Q. Liu, S. Lisboa, G. E. F. Scherer, H. Quader, and R. Malho
Phosphoinositides and phosphatidic acid regulate pollen tube growth and reorientation through modulation of [Ca2+]c and membrane secretion
J. Exp. Bot.,
June 1, 2005;
56(416):
1665 - 1674.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E.-M. Hur, Y.-S. Park, Y. H. Huh, S. H. Yoo, K.-C. Woo, B.-H. Choi, and K.-T. Kim
Junctional membrane inositol 1,4,5-trisphosphate receptor complex coordinates sensitization of the silent EGF-induced Ca2+ signaling
J. Cell Biol.,
May 23, 2005;
169(4):
657 - 667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Mignen, J. L. Thompson, D. I. Yule, and T. J. Shuttleworth
Agonist activation of arachidonate-regulated Ca2+-selective (ARC) channels in murine parotid and pancreatic acinar cells
J. Physiol.,
May 1, 2005;
564(3):
791 - 801.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Brown, J. I. E. Bruce, S. V. Straub, and D. I. Yule
cAMP Potentiates ATP-evoked Calcium Signaling in Human Parotid Acinar Cells
J. Biol. Chem.,
September 17, 2004;
279(38):
39485 - 39494.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Yao, Q. Li, J. Chen, and S. Muallem
Subpopulation of Store-operated Ca2+ Channels Regulate Ca2+-induced Ca2+ Release in Non-excitable Cells
J. Biol. Chem.,
May 14, 2004;
279(20):
21511 - 21519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. O'Flaherty, E. de Lamirande, and C. Gagnon
Phosphorylation of the Arginine-X-X-(Serine/Threonine) motif in human sperm proteins during capacitation: modulation and protein kinase A dependency
Mol. Hum. Reprod.,
May 1, 2004;
10(5):
355 - 363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. I. E. Bruce, D. R. Giovannucci, G. Blinder, T. J. Shuttleworth, and D. I. Yule
Modulation of [Ca2+]i Signaling Dynamics and Metabolism by Perinuclear Mitochondria in Mouse Parotid Acinar Cells
J. Biol. Chem.,
March 26, 2004;
279(13):
12909 - 12917.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Montero, C. D. Lobaton, S. Gutierrez-Fernandez, A. Moreno, and J. Alvarez
Modulation of Histamine-induced Ca2+ Release by Protein Kinase C: EFFECTS ON CYTOSOLIC AND MITOCHONDRIAL [Ca2+] PEAKS
J. Biol. Chem.,
December 12, 2003;
278(50):
49972 - 49979.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. Wagner II, W.-H. Li, and D. I. Yule
Phosphorylation of Type-1 Inositol 1,4,5-Trisphosphate Receptors by Cyclic Nucleotide-dependent Protein Kinases: A MUTATIONAL ANALYSIS OF THE FUNCTIONALLY IMPORTANT SITES IN THE S2+ AND S2- SPLICE VARIANTS
J. Biol. Chem.,
November 14, 2003;
278(46):
45811 - 45817.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Harayama
Viability and Protein Phosphorylation Patterns of Boar Spermatozoa Agglutinated by Treatment With a Cell-Permeable Cyclic Adenosine 3',5'-Monophosphate Analog
J Androl,
November 1, 2003;
24(6):
831 - 842.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Mignen, J. L. Thompson, and T. J. Shuttleworth
Ca2+ Selectivity and Fatty Acid Specificity of the Noncapacitative, Arachidonate-regulated Ca2+ (ARC) Channels
J. Biol. Chem.,
March 14, 2003;
278(12):
10174 - 10181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Baillie, A. Sood, I. McPhee, I. Gall, S. J. Perry, R. J. Lefkowitz, and M. D. Houslay
beta -Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta -adrenoceptor switching from Gs to Gi
PNAS,
February 4, 2003;
100(3):
940 - 945.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. I. E. Bruce, D. I. Yule, and T. J. Shuttleworth
Ca2+-dependent Protein Kinase-A Modulation of the Plasma Membrane Ca2+-ATPase in Parotid Acinar Cells
J. Biol. Chem.,
December 6, 2002;
277(50):
48172 - 48181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. deSouza, S. Reiken, K. Ondrias, Y.-m. Yang, S. Matkovich, and A. R. Marks
Protein Kinase A and Two Phosphatases Are Components of the Inositol 1,4,5-Trisphosphate Receptor Macromolecular Signaling Complex
J. Biol. Chem.,
October 11, 2002;
277(42):
39397 - 39400.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. V. Straub, D. R. Giovannucci, J. I. E. Bruce, and D. I. Yule
A Role for Phosphorylation of Inositol 1,4,5-Trisphosphate Receptors in Defining Calcium Signals Induced by Peptide Agonists in Pancreatic Acinar Cells
J. Biol. Chem.,
August 23, 2002;
277(35):
31949 - 31956.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|